Cybin has now dosed the first patients in its Phase 1/2a trial clinical trial investigating in psilocybin analogue CYB003 for the treatment of major depressive disorder...
Heroic Hearts Project and Maya PBC are partnering to generate the largest structured dataset illustrating the health outcomes of psychedelic treatments for veterans and their family...
A study by researchers at NYU Grossman School of Medicine has found that two doses of psilocybin reduced heavy drinking by 83 per cent when combined...
Unlimited Sciences, a psychedelic research nonprofit, will be carrying out an observational research study that will measure the potential healing effects of Ayahuasca on individuals with...
Launched by Subreddit r/HPPD in partnership with the scientific research app Quantified Citizen, the retrospective, observational study aims to investigate possible links between Hallucinogen Persisting Perception...
Psyched Wellness has announced preliminary data from tests completed by the National Research Council of Canada (NRC) on its extract AME-1.
The UNC School of Medicine has found that variants in one serotonin receptor in neurons could be why some patients fare much better after psychedelic therapy...
The Phase II clinical trial will test the efficacy of psilocybin on treatment resistant Post Traumatic Stress Disorder (PTSD).
Origin Therapeutics has completed an investment in Clairvoyant Therapeutics which will now proceed with a Phase 2 clinical trial for the clinical validation of psilocybin for the treatment of alcohol use...
Clinilabs Drug Development Corporation has begun enrolment in a Phase 1/2a clinical trial of Cybin’s CYB003 for the treatment of major depressive disorder (MDD).